Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
CIG media group
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study
Açıklama
Anahtar Kelimeler
Kaynak
Clinical lymphoma, myeloma and leukemia
WoS Q Değeri
Q2
Scopus Q Değeri
Cilt
24
Sayı
Künye
Quach, H., Dimopoulos, M., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., ... & Trudel, S. (2024). Characterization and Management of Ocular Events in Patients Treated with Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24, S273-S273.
